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 To study the function of the
Krüppel-like transcription factor KLF13
in vivo we generated mice with a
disrupted Klf13 allele.  Whilst Klf13-/-
mice are viable, fewer mice were present
at 3 weeks than predicted by Mendelian
inheritance.  Viable Klf13-/- m i c e h a d
reduced numbers of circulating
erythrocytes and a larger spleen.  The
spleen contained an increased number of
Ter119medCD71hi, Ter119hiCD71hi a n d
Ter119hiCD71m e d  ce l l s  but  not
Ter119hiCD71- cells indicating an increase
in less mature erythroblasts.  A higher
proportion of the Ter119medCD71hi cells
were proliferating indicating that the
mice were under a degree of
erythropoietic stress.  These data indicate
that KLF13 is involved in the normal
control of erythropoiesis.
Erythrocytes differentiate from multi-
potential haematopoietic stem cells through
a series of intermediates.  The first
committed erythrocyte precursors are the
burst forming unit cells (BFU-E) which
differentiate into colony forming units
(CFU-E) and then to proerythroblasts (1). As
these cells differentiate further through the
b a s o p h i l i c ,  p o l y c h r o m a t i c  a n d
orthochromatic erythroblast stages the
nucleus shrinks and is finally shed as the
cells become reticulocytes before becoming
erythrocytes (2).  During these later stages of
differentiation the cells lose expression of
CD71 and gain the expression of ter119 so
that these cell surface markers can be used to
differentiate the different cell stages (3).
The process of erythrocyte differentiation is
controlled by a number of different
transcription factors and regulated such that
under normal conditions sufficient
erythrocytes are produced predominantly by
the bone marrow but under conditions of
erythropoietic stress (e.g. hypoxia) the
number of erythrocytes can be increased and
this occurs predominantly in the spleen
(4,5).
Analysis of the transcriptional
program control l ing erythroblas t
differentiation has identified a number of
different transcription factors that are critical
to the normal development of erythrocytes
(1,2,6).  The best studied of these factors
regulating erythroid differentiation is
GATA-1 a zinc finger transcription factor
initially identified as a protein that bound to
the globin genes and activated their
expression (7).  Loss of GATA-1 leads to a
failure of erythropoiesis early in gestation
resulting in death of the embryos from
severe anaemia by E10.5 (8).  The
erythroblasts in these embryos fail to
develop past a pro-erythroblast like stage.
Another transcription factor that has
been studied extensively in erythrocytes is
the Krüppel-like factor (KLF) EKLF/KLF1,
a member of a family of at least 16
transcription factors (9,10).  Members of this
family can both activate and repress
transcription through interaction with a
range of different transcription factors (e.g.
the GATA factors and NF-κB) and co-
factors (e.g. p300, mSin3A) (11-14).  KLF1
was first identified as a CACC box binding
factor expressed in erythroleukaemia cells
but not in monocytes/macrophages (15).
Mice that lack expression of Klf1 die at E16
from a severe anaemia indicating a critical
role for KLF1 in the formation of
erythrocytes (16).  At least 8 other xKLF
proteins (KLF2- 5, 8 and 11- 13) are
expressed in erythroid cell lines. Of these
KLF2, 5, 8 and 13 have been shown to bind
to CACCC boxes in globin promoters and
can modify promoter activity in transfection
assays (17).  KLF2 null mice die before
E14.5, from a defect in the formation of the
endothelium but also have reduced
expression of embryonic ε-globin although
expression of adult globin genes is normal
(18).
K L F 1 3  ( K L F 1 3
/BTEB3/FKLF2/RFLAT) is another xKLF
protein expressed in the haematopoietic
system (19,20).  Binding of KLF13 activates
the promoters of a number of erythroid
genes including γ -globin, GATA-1,
porphob i l inogen  deaminase  and
ferrochelatase in vitro (21).  KLF13 is highly
expressed in human peripheral blood
lymphocytes and binds to and activates the
RANTES promoter in late activated T cells
(20,22).  We showed that murine KLF13
was widely expressed during embryogenesis
with high levels of expression in the
developing heart, thymus and liver (19).
We have generated mice with a
targeted deletion of exon one of the Klf13
allele and found that these mice have
enlarged hearts and an increased
susceptibility to the formation of cardiac
vacuolar lesions (Keramatipour et al.
submitted).  To determine the role of Klf13
in the differentiation of erythroid cells we
have compared erythropoiesis in Klf13-/- and
Klf13+/+- mice.
EXPERIMENTAL PROCEDURES
Mice
Klf13-/- mice generated in the CCB
(129S6Sv/Ev) ES cell line were maintained
on this genetic background. Genotyping of
tail DNA was performed by PCR using
p r i m e r s  C A G 3 F
(GCCTCCGCTCGACGTCCCTAAGA) and
CAG3R (GCGCGCTCTTCTCCGGCTG) to
amplify the wild-type allele and INTF
(CTGGGGATGCGGTGGGCTCTA) and
INTR (GGGTGGCGAGACTCCAGCTC) to
amplify the Klf13 mutated allele.  All mice
were bred and maintained at the University
of Cambridge Combined Animal Facility in
accordance with the Animals (Scientific
Procedures) Act 1986.
Blood Analysis
Blood was taken from the vena cava
of Klf13+/+ and Klf13-/- mice. Clotting was
prevented by the addition of 0.5M tri-
potassium-EDTA. Each sample was read in
triplicate on an ABC Vet Automated Blood
Counter (Woodley Equipment Company
Ltd, Bolton, UK).
Flow Cytometry
Spleen and femur bones were
dissected from 7-8 week old female Klf13 -/-
mice and Klf13 +/+. Body and spleen weights
were recorded and splenocyte suspensions
were made by mechanical dissociation
through a 70µM strainer in the presence of
cold PBS and 2% fetal calf serum
(PBS/2%FCS). Bone marrow (BM) cells
were extracted from femur bones using a
25G needle  and resuspended in
PBS/2%FCS.
Cel l s  were  s ta ined  us ing
c o m b i n a t i o n s  of directly conjugated
antibodies obtained from BD Pharmingen
(San Diego, CA: anti-CD4FITC, anti-CD4PE,
anti-CD4Cychrome,  anti-CD8FITC, anti-CD8P E,
anti-CD8Cychrome, anti-CD3F I T C,  anti-
CD71FITC, anti-Ter119PE, anti-CD45PE, and
anti-c-kitFITC .
Cell suspensions were stained with the
antibodies for 30 minutes on ice in 50 µL
Dulbecco modified medium (Life
Technologies, G a i t h e r s b u r g ,  M D ) ,
supplemented with 5% fetal calf serum
(FCS) and 0.01% sodium azide. Cells were
washed in this medium between incubations
and prior to analysis on the FACScan
(fluorescence-activated cell scan; Becton
Dickinson, Franklin Lakes, NJ). Events were
collected in list mode using CellQuest
software (Becton Dickinson), and data were
analyzed using CellQuest Pro software. Live
cells were gated according to their FSC and
SSC profiles. Data are representative of at
least 3 experiments. Intracellular staining for
cyclin B1 was performed on cells stained for
surface markers as above following fixation
a n d  permeabil isat ion with the
Cytofix/Cytoperm™ solutions (BD
biosciences) according to the manufacturer’s
instructions.
Fluorescence Activated Cell Sorting
(FACS) and Quantitative Reverse
Transcription PCR (QRT-PCR)
Splenocyte suspensions were stained
with antibodies against CD19PE, (BD
Pharmingen, San Diego, CA), Ter119PE, and
CD71FITC (eBioscience, San Diego, CA)
before being sorted on a DakoCytomation
MoFlo sorter. Only cells falling within the
forward scatter/side scatter (FSC/SSC) live
gate were sorted.
For purification using magnetic
beads, splenocytes were incubated on ice
with biotin labelled anti Ter119 at 1µg/106
cells for 30 min before 50µl of streptavidin
magnetic beads were added.  After a further
10 min on ice the samples were placed
against a magnet until the beads were
against the side of the tube.  Samples were
washed by resuspension in PBS +2% FCS 3
times before being resuspended in 300µl of
RLT buffer (Qiagen) for RNA purification.
Total RNA from sorted cells was
extracted using RNAeasy (Qiagen, Valencia,
CA).  Reverse transcription and quantitative
real-time PCR were performed as described
previously (23).  Primer sequences are
available on request. Klf13 transcript levels
for each sample were normalised to rRNA
levels which were amplified using TaqMan
Universal PCR Master Mix (Applied
Biosystems, Warrington, UK).
BFU-E and CFU-E colony forming assays.
BFU-E and CFU-E cultures were
performed using the methocult system
(StemCell Technologies) according to
manufacturer’s instructions. In brief, BM
and spleen cells were plated at a density of 2
x 10(5) cells per ml 1% methylcellulose
medium containing 15% FBS, 1% BSA,
10ug/ml insulin, 200ug/ml transferrin and
3U/ l EPO C lt i b t d t
37oC in 5% CO2. CFU-E were enumerated
after 2 days in culture and BFU-E after 3-4
days in culture. All cultures were done in
duplicate and each experiment repeated
eight times.
Statistical Analysis
Statistical analyses for differences between
Klf13+/+ and Klf13-/- mice were performed
using the two tailed Student’s t test
assuming unequal variance. Data are
presented as mean ± SD with n values given
in the corresponding figure legends.
RESULTS
Generation of the Targeting Construct
A genomic clone containing the
mouse Klf13 gene (PAC F69-B12) was
obtained by screening the mouse genome
filter set RCP121 with the full length (1200
bp) Klf13  coding sequence (Genbank
accession No.  AJ245644).  In silico
comparison of the Klf13 coding sequence
w i t h  t h e  g e n o m i c  s e q u e n c e
(ENSMUSG00000052040) together with
experimental verification by Southern
analysis and PCR showed that the Klf13
gene consisted of two exons.  Exon 1 codes
for the transactivation domain and the first
zinc finger of the protein and exon 2 codes
for the other two zinc fingers.  To identify
the start of the first exon, the 5’ end of the
known coding sequence together with 200bp
of presumed upstream sequence identified
from the mouse htgs database was compared
with the EST database using the BLAST
algorithm.  The majority of the EST
sequences containing the 5’ part of the Klf13
coding sequence stopped at one of two
positions separated by 30 nucleotides
indicating the presence of two
transcriptional start sites (Fig. 1A).  The
sequence upstream of the start sites did not
contain a TATA box indicating that Klf13
has a TATA-less promoter.  To generate a
vector to delete the first exon of Klf13 a
1.5kb fragment (mouse chromosome 7,
nucleotides 59688488 to 59689967) of the
promoter region and 4.9 kb of the intron
(chromosome 7, nucleotides 59682698 to
59687527) were amplified by PCR and
cloned into the vector pKO-DTA along with
a neomycin resistance cassette.  All the
fragments and the final targeting vector were
sequenced to confirm the PCR fidelity and
to result in a null allele.  The resulting vector
pDPN is shown in Fig. 1B.
To generate recombinant ES cells
with a targeted mutation in Klf13, pDPN was
linearised in the vector backbone with PvuII
and electroporated into ES cells.  Cells were
selected in G418 and resistant clones were
picked and expanded.  DNA was extracted
from 45 clones and amplified by PCR using
primer PF and PR to identify clones with the
appropriate 5’ insertion of the DNA.  This
process identified 14 clones and DNA from
these clones was digested with EcoRI and
analysed by Southern blot.  Probing the blot
with a DNA probe to the 5kb intron gave a
band >13kb for the wild-type locus and an
11kb band for the targeted locus (Fig. 1C).
Twelve out of 45 clones contained the
targeted locus giving an overall targeting
frequency of 27% of the clones picked.  The
targeted ES cells were injected into C57Bl/6
blastocyts to generate transgenic mice.
Klf13 null mice
Genotyping of the offspring of the
mice was performed by PCR for both the
wild type and mutant alleles as shown in Fig
1D.  This analysis showed that whilst null
mice were detected after weaning, the
numbers were less than that predicted by
Mendelian inheritance (Table 1).  To
determine whether the lethality arose from
an early embryonic loss, embryos from
timed matings of Klf13+/- females with
Klf13-/- males were examined and genotyped
at E10.5 and E13.5.  At neither of these time
points was there any detectable deviation
from Mendelian ratios (n=31 embryos at
E=10.5 with 14 Klf13-/- and 17 Klf13+/-
embryos; n= 59 embryos at E13.5 with 30
Klf13+/- embryos and 29 Klf13-/- embryos).
The cause and time of onset of the lethality
has yet to be determined.  To confirm that
the Klf13-/- mice did not express KLF13
mRNA, RNA from the heart (a tissue which
expresses high levels of KLF13) was reverse
transcribed and amplified by PCR.  KLF13
mRNA was not detectable by this method in
Klf13-/- mice (Fig 1E).  Quantification of
mRNA from the heterozygous animals
suggested that these mice expressed
approximately half of the mRNA levels
expressed in wild-type mice (Fig 1F).  It is
therefore likely that KLF13 does not
l t it i
Altered blood cell composition in Klf13-/-
mice
To determine the effect of loss of
KLF13 on the haematopoietic system, blood
samples were taken and complete blood
counts determined.  Whilst the haematocrit
of Klf13-/- mice was the same as wild type
mice the numbers of red cells were reduced
by 10% and their size (MCV) was increased
(see Table 2).  Consequently the blood of the
Klf13-/- mice was populated with fewer but
larger red blood cells.  Despite the altered
erythrocyte profile, total haemoglobin levels
in the Klf13-/- mice were unaltered.  Klf13-/-
mice also had reduced numbers of
lymphocytes (to 70% of wild type) and a
trend towards reduced numbers of
granulocytes (to 76% of wild-type) and
monocytes (to 77% of wild-type) suggesting
that the loss of KLF13 affects the pathways
involved in the differentiation or survival of
the major blood cell types (Table 2). To
investigate the cause of the change in
erythrocytes in the blood we analysed the
cellular composition of the spleen.
Increased spleen size in Klf13-/- mice
Spleens removed from 7 week old
Klf13-/- mice were approximately 1.5 times
the weight of those removed from age and
sex matched Klf13+/+ mice (117±27 mg
Klf13-/- and 73±11mg Klf13+/+).  Similar
results were obtained with the spleen
weights normalised to body weight (5.5±1.2
mg/g body weight Klf13-/- and 3.73±0.6
mg/g body weight Klf13+/+, Fig, 2A).
Furthermore, there was a proportionate
increase in the number of cells isolated from
the spleens of Klf13-/- mice compared to
their Kl f13 + / +  counterparts (Fig 2B)
indicating that the increase in spleen size is
due to an increase in cell number rather than
fibrosis.
Flow cytometry using anti-CD3ε and
anti-CD19 showed a reduction in the
proportions of T and B cells in the spleens of
Klf13-/- mice (Fig 2C) which when adjusted
for spleen cell number showed no difference
in absolute lymphocyte number between
Klf13-/- and Klf1+/+ mice.  Consequently the
proportion of cells that did not stain for
CD3ε or CD19 increased from 10% in the
wild type mice to 33% in the Klf13-/- mice.
These data indicate that the increased
splenomegaly.  Staining the cells for CD45
identified three cell populations CD45- (Fig
2D), CD45med (Fig 2D upper left) and
CD45hi (Fig 2D upper right).  .The number
of CD45hi cells did not change (Klf13+/+;
1.05 ± 0.06 x 108 cells/spleen and Klf13-/-;
0.98 ± 0.2 x 108 cells/spleen) but there was a
marked 7-fold increase  (Klf13+/+; 5.8 ± 2.3 x
106 cells/spleen and Klf13-/-; 43.7 ±11.0x 106
cells/spleen) in the number of CD45med cells
and a 3-fold increase in the number of
CD45- cells in the spleens of Klf13-/- mice
(Klf13+/+; 12.6 ± 0.17 x 106 cells/spleen and
Klf13-/-; 41.8 ± 0.74 x 106 cells/spleen., Fig.
2E).  As CD45 is highly expressed on the
majority of lymphoid and myeloid cells it
was unlikely that the increased spleen mass
in Klf13-/- mice was attributable to cells of
these lineages. However, during erythroid
cell development, Expression of CD45
decreases as erythroblasts mature into
erythrocytes suggesting that the increase in
spleen size in Klf13-/- mice could be due to
alterations in the erythroid lineage.
Abnormal erythroblast maturation
in Klf13 -/- mice
To determine whether the increase
in cell number was due to an expansion of
cells of the erythroblast lineage, splenocytes
from Klf13-/- and Klf13+/+ mice were stained
for Ter119 and CD71. The expression of
these markers distinguishes at least four
populations of erythroid cells which are,
from least to most differentiated,
Ter119medCD71hi,  T e r 1 1 9hiCD71hi,
Ter119hiCD71med and Ter119hiCD71low Fig
3A (3). These populations are represented in
Figure 3B as I, II, III and IV respectively
and can be further characterised by their size
with an overall decrease in cell size from
type I to Type IV. flow cytometric analysis
(Fig. 3A) showed a seven fold expansion of
Ter119medCD71hi from 2.2 ± 1.0 x 105
cells/spleen in the Klf13+/+ mice to 15.6 ±
8.9 x 105 cells/spleen in the Klf13-/- mice,
and Ter119hiCD71hi from 3.4 ± 2.3 x 106
cells/spleen in the Klf13+/+ mice to 15.6 x
106 cells/spleen in the Klf13-/- mice and a
three fold expansion of Ter119hiCD71med
from 9.3 x 106 cells/spleen in the Klf13+/+
mice to 21.9 x 106 cells/spleen in the Klf13-/-
mice (Fig. 3B). However, despite this
increase in erythroid precursors, numbers of
late erythroblasts (Ter119hiCD71low,
ch roma toph i l i c  e ry th roba l s t s  to
reticulocytes) remained unaltered.
The alterations in erythropoiesis may
have resulted from indirect effects rather
than loss of KLF13 in the erythroblasts.  We
therefore determined whether Klf13 was
expressed in erythroblasts.  Quantifying
Klf13 mRNA in erythroblasts sorted by
FACS from the spleens of Klf13+/+ mice
showed that Klf13 expression increased
between Ter119+CD71+ erythroblasts and
Ter119+CD71- erythroblasts (2.5-fold, Fig.
3C).  These levels of Klf13 mRNA in
Ter119+CD71- erythroblasts are similar to
those in splenic CD4+ and CD8+ T cells
CD19+, and 10-fold higher than splenic B
cells (Outram, et al. submitted). Therefore,
Klf13  expression increases as erythroid
precursors mature suggesting a direct
involvement of KLF13 in erythroblast
differentiation.
Erythropoiesis in the BM
Whilst some erythropoiesis occurs in
the spleen under normal conditions, most
splenic erythropoiesis occurs as a response
to haematologic stress (5). The process of
normal erythropoiesis occurs mostly in the
BM.  Therefore to determine whether the
same defects occurred in erythropoiesis in
the BM we determined the proportion of
type I to type IV cells in the BM.  This
analysis showed an increase in type II
erythroblasts (p<0.03) in the BM and a trend
to an increase in the number of type I cells
but this did not reach significance (p=0.06).
There was no effect on the other erythroblast
populations (Fig. 3D).
To analyse the ability of progenitors
from Klf13-/-mice to differentiate along the
erythropoietic lineage we determined the
number of BFU-Es and CFU-Es in the
spleen.  Consistent with the increase in
Ter119medCD71hi cells both BFU-Es and
CFU-Es were increased in the spleen (Figs
3E and 3F).   In the BM there was no change
in the number of CFU-E or BFU-E.
Together with the CD71/Ter119 staining
these data suggest that loss of KLF13 does
not inhibit the commitment of cells to the
erythrocyte lineage.
Expression of transcription factors
involved in erythropoiesis
To determine whether the expression
of other transcription factors known to be
i l d i th diff ti ti f
erythrocytes was altered by the lack of
Klf13 , we determined the expression of
GATA-1, KLF1 and KLF3 by Q-RTPCR in
Ter119+ cells isolated by magnetic bead
separation from the spleens of Klf13-/- and
Klf13+/+ mice.  The mRNA for all of these
transcription factors increased at least 3-fold
in the erythroblasts of Klf13-/- mice (Fig.
4A).  It is possible that the increase in the
mRNA for these transcription factors was
due to differences in the proportion of
immature Ter119+ cells in the samples from
the different mice.  We therefore compared
the expression of the same factors in the
FACS sorted Ter119+ C D 7 1- a n d
Ter119+CD71+  cells from Klf13+/+ mice.
The mRNAs for both GATA-1 and KLF1
were 4-6 fold higher in the Ter119+CD71+
cells (Fig. 4B) making it likely that the
increase in these mRNAs results from an
increase in the number of less mature cells in
the Klf13-/- mice.  However, the expression
of Klf3 was lower in Ter119+CD71+ cells
compared to Ter119+CD71- indicating that
loss of KLF13 had resulted in an increase in
Klf3 expression (Fig. 4A).
Erythroid cell proliferation in
KLF13-/- mice
To determine whether the loss of
K l f 1 3  altered the proliferation of
erythroblasts cyclin B expression was
measured in Ter119med and Ter119hi cells.
Cyclin B expression was increased in
Ter119med cells but not in Ter119hi cells of
the Klf13-/- mice.  These data indicate that
the cell proliferation increased in type I cells
but not in more mature erythroblasts (Fig.
5A).
Altered expression of apoptosis
associated genes in KLF13-/- mice
The final stages of erythroid
differentiation requires the expression of
genes associated with apoptosis (2).
Therefore, we determined the expression of
the major determinants of apoptosis in
Ter119+ve cells by Q-RT-PCR.  This analysis
showed that there was no change in the
expression of Bad or Bcl-2 and a trend
towards an increase in the expression of Bax
but this did not reach significance (Fig. 5B).
However there was a marked (4.5 fold)
increase in the expression of Bcl-xL in the
splenocytes from Klf13-/- mice compared to
their wild-type counterparts (Fig. 5B).  To
d t i h th thi i i B l L
was due to the increase in the proportion of
CD71 positive cells in the Ter119+
population Bcl-xL, Bad and Bax and Bcl2
were measured in FACS sorted populations
of CD71+:Ter119 + and CD71-:Ter119+
splenocytes from wild-type mice.  This
analysis showed that Bcl-xL expression was
higher in the CD71+:Ter119- cells than in the
CD71+:Ter119+ cells consequently much of
the increased amount of Bcl-xL observed in
the KLF13-/- mice is likely to arise from the
increase in proportion of immature cells in
the spleens of these mice (Fig 5C).
Consistent with these observations we did
not observe a significant reduction in
apoptosis in Ter119+ cells by annexin
staining.  During the preparation of this
paper Zhou et al (24) published their
analysis of a similar line of KLF13-/- mice.
This analysis showed a marked reduction in
apoptosis and increased expression of Bcl-
xL in thymocytes.  Thus it appears that Bcl-
xL is a major target of KLF13 in thymocytes
but not in erythrocytes.
DISCUSSION
Previous studies have implicated
Klf13 in the differentiation of erythrocytes in
vitro(17,22).  Our data demonstrate a role
for Klf13 in these cells in vivo by showing
that there is an increase in the number of
immature erythrocytes in the spleens of mice
that lack expression of Klf13.  Indeed the
reduced levels of other cell types in the
circulation of the Klf13-/- mice suggest that
Klf13  is required for the differentiation
and/or proliferation of other haematopoietic
cell lineages.
Our data indicate that the cells were
able to commit to the erythrocyte lineage as
there was no change in the number of BFU-
Es or CFU-Es in the bone marrow.
However the cells accumulate in the
proerythroblast stage of development and
have increased expression of KLF3.  Mice
that lack KLF3 have also been shown to
have splenomegaly although the mechanism
behind this phenotype is unexplored raising
the possibility that both KLF13 and KLF3
act at the same point but that the increase in
KLF3 is insufficient to overcome the loss of
KLF13.  An alternative explanation of these
data is that KLF13 is an inhibitor of Klf3
expression in erythroblasts.
 Erythropoiesis is disrupted in several
other lines of mice with targeted mutations
to transcription factors.  For example, both
GATA-1 and KLF1 are required for
erythropoiesis to occur mice (8,16).  Mice
with low levels of expression of GATA-1
survive but become increasingly anaemic
with age (25) and show stress erythropoiesis
as a compensation for defective primary
erythropoiesis.  This phenotype is similar to
that seen in lyn-/- mice which have reduced
expression of GATA-1 and KLF1 (26).   The
splenomegaly observed in our mice is also
consistent with a stress erythropoietic
response.  However, in our mice we found
little change in the expression of both Klf1
and GATA-1 in Ter119+ cells in contrast to
the data from lyn-/- mice.  This difference
suggests that Klf13 regulates a different
stage of erythropoiesis to that regulated by
KLF1 and GATA-1.  Furthermore, it
suggests that although KLF13 is known to
bind to and activate the GATA-1 promoter it
is not a major regulator of GATA-1
expression.  However, it is also possible that
KLF13 interacts with and/or cooperates with
GATA-1 to drive a subset of GATA-1
functions in erythropoiesis.  Such an
interaction has recently been shown between
GATA-4 and KLF13 in Xenopus and results
in a failure of cardiac development and a
reduction in the expression of B-type
naturietic peptide in this model (27).  The
extent of any requirement for KLF13 in the
function of GATA-1 is also dependent on
the ability of other KLF proteins to
compensate for the loss of KLF13 in some
but not all activities of GATA-1.
Apoptosis of erythrocytes occurs in
the spleen as a feedback mechanism to
regulate the number of erythrocytes and
splenomegaly has been shown in mice with
aberrant apoptosis(28,29).  It was therefore
possible that loss of Klf13 resulted in a
reduction in apoptosis and consistent with
this suggestion during the preparation of this
paper Zhou et al (24) published their
analysis of Klf13-/- mice and showed that
KLF13 was an inhibitor of the expression of
the antiapoptotic factor Bcl-xL.   However,
in our mice there was no significant change
in annexin staining in Ter119+ cells
suggesting that there was no increase in
apoptosis in these mice.  Furthermore we
found no detectable increase in Bcl-xL
expression once the change in proportion of
immature cells was accounted for.
However, we did detect an increase in the
expression of cyclin B in Ter119+ cells
suggesting an increase in proliferation.
Together these data suggest that increased
proliferation rather than a reduction in
apoptosis leads to the increase in spleen size.
In summary the data presented here
identify a role for Klf13 in the maturation of
erythrocytes.  Loss of Klf13 results in an
increase in the expression of Klf3 and cyclin
B but other Klf13 target genes in
erythroblasts remain to be identified.
Acknowledgements
Funding
This work was supported by the British Heart Foundation grant No PG/02/135/14620 to P.K
and J.M.  S.O was supported by the BBSRC and AH-T was supported by the Wellcome Trust.  CG
was supported by the MRC, WHC was supported by the Ford Physiology endowment fund.
The authors have no competing financial interests.
References
1. Perry, C., and Soreq, H. (2002) Eur J Biochem 269, 3607-3618
2. Koury, M. J., Sawyer, S. T., and Brandt, S. J. (2002) Curr Opin Hematol 9, 93-100
3. Zhang, J., Socolovsky, M., Gross, A. W., and Lodish, H. F. (2003) Blood 102, 3938-3946
4. Hara, H., and Ogawa, M. (1976) Am J Hematol 1, 453-458
5. Kam, H. Y., Ou, L. C., Thron, C. D., Smith, R. P., and Leiter, J. C. (1999) J Appl Physiol 87,
1901-1908
6. Moritz, K. M., Lim, G. B., and Wintour, E. M. (1997) Am J Physiol 273, R1829-1844
7. Wall, L., deBoer, E., and Grosveld, F. (1988) Genes Dev 2, 1089-1100
8. Fujiwara, Y., Browne, C. P., Cunniff, K., Goff, S. C., and Orkin, S. H. (1996) Proc Natl Acad
Sci U S A 93, 12355-12358
9. Kaczynski, J., Cook, T., and Urrutia, R. (2003) Genome Biol 4, 206
10 P ki A (1999) I J Bi h C ll Bi l 31 1175 1192
11. Feinberg, M. W., Cao, Z., Wara, A. K., Lebedeva, M. A., Senbanerjee, S., and Jain, M. K.
(2005) J Biol Chem 280, 38247-38258
12. Matsumura, T., Suzuki, T., Aizawa, K., Munemasa, Y., Muto, S., Horikoshi, M., and Nagai,
R. (2005) J Biol Chem 280, 12123-12129
13. Song, C. Z., Keller, K., Chen, Y., and Stamatoyannopoulos, G. (2003) J Mol Biol 329, 207-
215
14. Ellenrieder, V., Zhang, J. S., Kaczynski, J., and Urrutia, R. (2002) Embo J 21, 2451-2460
15. Miller, I. J., and Bieker, J. J. (1993) Mol Cell Biol 13, 2776-2786
16. Perkins, A. C., Sharpe, A. H., and Orkin, S. H. (1995) Nature 375, 318-322
17. Zhang, P., Basu, P., Redmond, L. C., Morris, P. E., Rupon, J. W., Ginder, G. D., and Lloyd, J.
A. (2005) Blood Cells Mol Dis 35, 227-235
18. Wani, M. A., Means, R. T., Jr., and Lingrel, J. B. (1998) Transgenic Res 7, 229-238
19. Martin, K. M., Metcalfe, J. C., and Kemp, P. R. (2001) Mech Dev 103, 149-151.
20. Song, A., Chen, Y. F., Thamatrakoln, K., Storm, T. A., and Krensky, A. M. (1999) Immunity
10, 93-103.
21. Asano, H., Li, X. S., and Stamatoyannopoulos, G. (2000) Blood 95, 3578-3584
22. Nikolcheva, T., Pyronnet, S., Chou, S. Y., Sonenberg, N., Song, A., Clayberger, C., and
Krensky, A. M. (2002) J Clin Invest 110, 119-126.
23. Ellis, P. D., Smith, C. W., and Kemp, P. (2004) J Biol Chem 279, 36660-36669
24. Zhou, M., McPherson, L., Feng, D., Song, A., Dong, C., Lyu, S. C., Zhou, L., Shi, X., Ahn,
Y. T., Wang, D., Clayberger, C., and Krensky, A. M. (2007) J Immunol 178, 5496-5504
25. Takahashi, S., Komeno, T., Suwabe, N., Yoh, K., Nakajima, O., Nishimura, S., Kuroha, T.,
Nagasawa, T., and Yamamoto, M. (1998) Blood 92, 434-442
26. Ingley, E., McCarthy, D. J., Pore, J. R., Sarna, M. K., Adenan, A. S., Wright, M. J., Erber,
W., Tilbrook, P. A., and Klinken, S. P. (2005) Oncogene 24, 336-343
27. Lavallee, G., Andelfinger, G., Nadeau, M., Lefebvre, C., Nemer, G., Horb, M. E., and Nemer,
M. (2006) Embo J 25, 5201-5213
28. Diwan, A., Koesters, A. G., Odley, A. M., Pushkaran, S., Baines, C. P., Spike, B. T., Daria,
D., Jegga, A. G., Geiger, H., Aronow, B. J., Molkentin, J. D., Macleod, K. F., Kalfa, T. A.,
and Dorn, G. W., 2nd. (2007) Proc Natl Acad Sci U S A 104, 6794-6799
29. Rhodes, M. M., Kopsombut, P., Bondurant, M. C., Price, J. O., and Koury, M. J. (2005)
Blood 106, 1857-1863
Figure legends
Figure 1. Targeting the Klf13 locus
A. The 5’ region of the Klf13 mRNA. Start sites identified by BLAST comparison with the EST
database are indicated by (_) and the translation start site is underlined. B. The wild-type Klf13 locus,
linearised targeting construct and targeted allele are shown. Klf13 exons are shown as filled black
rectangles. Boxes marked Neo and DT-A show the positions of the neomycin and Diphtheria toxin A
selection cassettes respectively. Arrows mark the positions of primers used for genotyping (1; B3F, 2;
B3R, 3; MutF, 4; MutR). The positions of EcoRI sites are marked by E and the probe used for
Southern hybridisation is marked by a thick line. C. Southern analysis of ES cell clones. DNA
extracted from ES cells was digested with EcoRI. Southern blots of the DNA were probed with a 4kb
fragment of the intron. D. PCR genotyping of wild-type, heterozygous and homozygous null mice.
DNA from ear clips was amplified using primers B3F, B3R, MutF and MutR and the products
analysed on a 2% agarose gel. The bands sizes are 185bp (wild type) and 226bp (mutant).  E. RT-
PCR for Klf13 mRNA in the hearts of Klf13+/+, Klf13+/- and Klf13-/- mice.  Klf13 mRNA produces a
185bp product. No products were observed in the absence of reverse transcription indicating that the
samples were not contaminated with genomic DNA. M. Marker lane (Hyperladder I). F. Relative
expression of KLF13 determined by quantitative real-time PCR of cDNA from the right ventricle
(n=5 samples for each genotype). Messenger RNAs were quantified by calculating Ct and normalised
to the Ct value for rRNA as described previously
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Figure 2.  Deletion  of  Klf13 results in increased spleen size
Spleens were taken from 7 week old female Klf13-/- mice and their wild-type counterparts.
The spleens were weighed and compared to the body weight of the mouse (n=26 of each genotype)
(A ). Splenocyte suspensions were prepared as described in Materials and Methods and the cells
counted on a haemocytometer (n=7 of each genotype) (B). Cell suspensions were stained with anti-
CD19 and anti-CD3 and analysed by flow cytometry.  There was a large increase in the percentage (3
fold, n = 12 mice) of unstained cells. Cell percentages from a representative experiment are shown
(C).  Cells were stained for CD45; CD45- (bottom left hand area), CD45med (box R2) and CD45hi (box
R3) (D). The cells in these areas were quantified and normalised to the average for wild-type mice (E)
(n = 6 mice for each line).  All data are mean ± SD, * p<0.02, **p<0.005, *** p<0.0001 wt vs Klf13-/-
)..
Figure 3. Increased erythropoiesis in in Klf13-/- mice
A . Ter119 and CD71 staining of splenocytes from Klf13-/- and wild-type mice identified four
erythroblast populations (I to IV; values given are mean percentages corrected for spleen size). The
overlay plots shows the CD71 fluorescence profile of populations II and III from a wild-type and
klf13-/- mouse.  The four populations identified in (A) populations were quantified (B) and normalised
to the average number in wild type mice (data are mean ± SD, n = 6 mice for each line).  Clear bars
represent wild-type and b1ack bars represent Klf13-/- mice. C. Splenocytes from wild-type mice were
stained with antibodies to ter119 and CD71 and sorted by FACS. A minimum of 105 cells were
collected for each population and the RNA extracted.  RNA was reverse transcribed and amplified in
real-time PCR reactions using primers for Klf13. Klf13 mRNA was normalised to rRNA.  D. Femoral
bone marrow cells were stained with Ter119 and CD71 and separated by FACS.  The four
erythroblast populations were quantified and normalised to the average number in wild-type mice (n =
6 mice of each genotype). Splenocytes and bone marrow cells from wild type and Klf13-/- mice were
cultured in methylcellulose as described in Materials and Methods.   Numbers of CFU-E colonies (E)
and BFU-E colonies (F) on each plate were normalised to the average number of colonies on the
plates from wild-type mice (n=8 for each line). All data are presented as mean ± SD, * p<0.03,
**p<0.01 wt vs Klf13-/-)
Fig 4. Effect of loss of Klf13 on the expression of Gata-1, Klf1, and Klf3
 RNA was extracted from (A) Ter119 positive splenocytes isolated on magnetic beads or (B) Ter119
and CD71 stained, FACS sorted splenocytes.  Gata-1, Klf1, and Klf3 mRNAs were quantified by
quantitative real-time PCR normalised to Gapdh (n = 5 mice for each line, mRNA samples were
prepared and analysed from each mouse independently).  Data are presented as mean ± SD, * p<0.03
wt vs Klf13-/-.
Figure 5.  Cell proliferation and apoptosis in Klf13-/- mice
Splenocytes were stained for Ter119 and cyclin B (A).  Spleens from Klf13-/- mice had
increased numbers of Ter119med cells expressing cyclin B1 compared to those of wild-type mice (n=3
mice of each genotype).  RNA was extracted from (B) Ter119 positive splenocytes isolated on
magnetic beads or (C) Ter119 and CD71 stained, FACS sorted splenocytes.  Bcl-XL, Bad, Bax, and
Bcl2 mRNAs were quantified by quantitative real-time PCR normalised to Gapdh (n = 5 mice for
each line, mRNA samples were prepared and analysed from each mouse independently).  Data are
presented as mean ± SD, * p<0.05, **p<0.01, wt vs Klf13-/-).
Table 1.  Genotype ratios of mice born to KLF13+/- parents
Offspring number +/+ +/- -/-
actual 131 285 98
predicted 129 258 129
Chi squared =10.3 p<0.01
Table 2.  Blood cell counts
Klf13+/+ Klf13-/-
MEAN
(n=5)
STDEV Reference
range
(mean ±
2SD)
MEAN
(n=4)
STDEV t-test
p
value
WBC 9.36 0.78 10.9-7.8 6.75 0.89 0.003
RBC 10.54 0.52 11.5-9.5 9.54 0.55 0.03
HGB 16.7 0.5 17.6-15.7 16.0 0.84 NS
HCT 51 1.50 53.9-47.9 49.0 2.44 NS
MCV 48.3 1.55 51.4-45.2 51.5 0.43 0.008
MCH 15.9 0.46 16.7-14.9 16.8 0.19 0.006
MCHC 32.7 0.24 33.1-32.25 32.7 0.08 NS
PLTS 458 50 557-358 437 113.42 NS
MPV 5.03 0.09 5.21-4.85 4.98 0.13 NS
RDW 13.71 0.42 14.5-12.9 14.36 0.11 0.024
LYMP 6.50 0.69 7.88-5.12 4.56 0.51 0.002
MONO 1.33 0.06 1.45-1.21 1.01 0.21 0.054
GRAN 1.53 0.22 1.97-1.09 1.18 0.28 0.08
Legend
WBC; white blood cell count (x103/mL), RBC red blood cell count (x106/ul), HGB;
haemoglobin concentration (g/dL), HCT; haematocrit (%), MCV mean corpuscle volume (fL), MCH;
mean corpuscle haemoglobin (pg), MCHC, mean corpuscle haemoglobin concentration (g/dL), PLTS;
number of platelets (x 103/ul), MPV; mean platelet volume (fL), RDW; red cell distribution width,
Lymp; lymphocyte number (x103/mL), Mono; Monocyte number (x103/mL), Gran; granulocyte
number (x103/mL).  The reference range has been calculated as 2 standard deviations from the mean
of the wild-type population.
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